Site activation is taking longer than five months at 55% of clinical trial sites in 2025, contract and budget delays are hampering 66% of those sites frequently, and Phase II trial terminations climbed to 31% last year, up from 29% in 2023 and a full ten percentage points above pre-pandemic norms. Those numbers are not a backdrop to WCG’s 2026 Clinical Research Trends and Insights Report; they are the operational argument for it. The industry keeps generating sophisticated science while the infrastructure beneath it frays, and WCG is positioning this report as a corrective lens for sponsors, CROs, and sites trying to close that gap.
The report organizes around four themes: AI and machine learning moving from pilot projects into embedded decision-making; site and investigator readiness treated as a durable, continuously measured asset rather than a pre-study checklist; participant experience redesigned around participant-driven rather than merely participant-centric models; and the operational complexity of cell and gene and advanced therapies. That last category deserves particular attention. Logistics, long-term follow-up requirements, and regulatory coordination for advanced therapies are categorically different from small-molecule work, and most site infrastructure was not built with them in mind. WCG, which reviews more than 3,000 new protocols and 15,000 new principal investigators annually, has the throughput data to identify where those mismatches are worst.
The AI governance thread running through the report is serious, not decorative. The FDA’s draft guidance on AI and machine learning supporting regulatory decision-making introduced a risk-based credibility assessment framework that requires sponsors to demonstrate how and when AI-generated information influences submissions. That is a compliance burden that most sites are not yet structured to absorb, and embedding AI without accountability architecture creates the kind of regulatory exposure that can stall a program far more than a slow site activation ever would.
The participant retention data is the pressure point to watch most closely here. A 31% Phase II termination rate signals that dropout and engagement failure are now consuming capital at scale, not just adding inconvenience. If the report’s participant-driven design argument translates into concrete protocol modifications that reduce early discontinuation, the downstream effect on Phase III success rates is the real measure of whether 2026 marks a genuine inflection or another year of well-organized problem statements.
Source link: https://cms.centerwatch.com/insights/wcg-2026-clinical-research-trends-insights-report/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
